For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

If you struggle with atrial fibrillation, evolving technologies at United Regional may be able to help your heart stay ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Lucia, a leader in health AI and patient engagement solutions, and the Heart Rhythm Society (HRS), the international leader ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Research reveals rise in AFib among younger people. Learn the warning signs, risk factors and how to protect your heart ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

During a fireside chat at the annual J.P. Morgan Healthcare Conference on January 13th, Mayo Clinic chief administrative ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...